2021. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s94. DOI:https://doi.org/10.25251/skin.5.supp.94.